Rani Therapeutics Holdings, Inc.
Rani Therapeutics Holdings, Inc. is a U.S.-based clinical-stage biotherapeutics company developing oral delivery technology for biologics and other drugs. Its core platform, the RaniPill capsule, is designed to deliver drug substances such as antibodies, proteins, peptides, and oligonucleotides through the gastrointestinal tract, with development activities centered in the United States and intended for global use.
Tilikausi 2025 · muutos edellisvuodesta
Kehitys 2020–2025
Liiketoiminta
Osuus liikevaihdostaMicrotablet-based oral capsule designed to deliver small biologic doses with high bioavailability.
High-capacity capsule under development for liquid payload delivery of larger biologics.
Technology evaluation, transfer, and collaboration work performed for third-party biopharma partners.
Asiakkaat
Rani’s customers are primarily biopharmaceutical companies that want to convert injectable biologics into oral therapies using its delivery platform. The company also serves potential development partners seeking evaluation, technology transfer, and collaboration around specific compounds and drug targets. End users of the technology are patients and healthcare systems, but the direct commercial customer is typically the drug developer or license partner.
Companies that license or co-develop the RaniPill platform for specific biologic or drug programs.
Partners that pay for evaluation services to assess whether their compounds can be delivered orally.
Drug developers that may adopt the platform for approved products if clinical and regulatory milestones are met.
Strategia
Rani’s strategy is to advance the RaniPill platform through clinical development while partnering with biopharma companies that want oral delivery for their biologics. A second priority is building manufacturing capability for the capsule and related device components so the platform can scale if programs succeed. The company also seeks collaboration structures that can fund development and create milestone and royalty economics.
Human data is needed to prove oral delivery performance and support regulatory progress.
Partner programs can create non-dilutive funding and validate the platform with named drug developers.
Commercial adoption will require reliable capsule manufacturing and supply chain control.
Maantiede
Rani is headquartered in the United States and conducts its development, engineering, and manufacturing activities primarily there. The company has indicated that future commercialization, if achieved, could extend to the United States, Europe, Asia, and other key markets through its own infrastructure or partners. Geography matters because the platform is intended for global pharmaceutical use, while regulatory approval and partner execution will determine where revenue is ultimately realized.
Riskit
Rani faces the typical risks of a clinical-stage biotechnology company: uncertain clinical outcomes, regulatory approval risk, and dependence on third-party partners and suppliers. Its business model also requires substantial capital before any commercial product revenue, so financing access and Nasdaq listing compliance are material to execution. Because the platform is still being developed, manufacturing scale-up, intellectual property protection, and partner commitment are all important sources of risk.
- Clinical and regulatory failureVaikutus: KriittinenTodennäköisyys: Korkea
The RaniPill platform must prove safety, bioavailability, and efficacy across programs.
Kohdistuu: RaniPill GO and RaniPill HC
- Lack of commercial product revenueVaikutus: KorkeaTodennäköisyys: Korkea
The company is still in development, so revenue depends on future approvals and partner execution.
Kohdistuu: Platform-wide
- Financing and dilution riskVaikutus: KorkeaTodennäköisyys: Korkea
Development and manufacturing require capital before product sales are available.
Kohdistuu: Corporate funding
- Partner concentration and collaboration dependenceVaikutus: KorkeaTodennäköisyys: Kohtalainen
A major portion of future economics may depend on one or a few collaboration agreements.
Kohdistuu: Chugai collaboration
- Supply chain and manufacturing executionVaikutus: KeskitasoTodennäköisyys: Korkea
The platform relies on third-party APIs/components and complex device manufacturing.
Kohdistuu - Nasdaq listing complianceVaikutus: KeskitasoTodennäköisyys: Korkea
Failure to maintain listing standards could reduce liquidity and investor access.
Kohdistuu: Public equity market access
Kirjanpito
Harkinnanvaraiset erätEvaluation services for partners like Chugai are recognized as services are delivered, affecting quarter-to-quarter revenue.
Vaikutus: Small but important for collaboration economics
Clinical work, engineering, materials, and stock compensation drive reported operating loss.
Vaikutus: Primary driver of period expenses
Assets with alternative future use may be capitalized, while other project costs are expensed.
Vaikutus: Affects balance sheet size and near-term earnings
Loss attribution between Rani and non-controlling interests changes reported net loss attributable to shareholders.
Vaikutus: Impacts earnings attribution
Samankaltaisia listattuja yhtiöitä
Julkisesti listattuja yhtiöitä, joilla on samankaltainen liiketoiminta.
Silence Therapeutics plc
SLNCF · Pharmaceutical Preparations
Silence Therapeutics plc is a biotechnology company focused on discovering and developing siRNA-based medicines that silence disease-associated genes through RNA interference.
Oncotelic Therapeutics, Inc.
OTLC · Pharmaceutical Preparations
Palisade Bio, Inc
PALI · Biological Products, (No Diagnostic Substances)
Oramed Pharmaceuticals Inc
ORMP · Pharmaceutical Preparations
Raphael Pharmaceutical Inc.
RAPH · Medicinal Chemicals & Botanical Products
GT Biopharma, Inc.
GTBP · Pharmaceutical Preparations
Päivitetty: 24.9.2026